CorticorpNews
Back to Finance
Expand

Updated

Shares of Genmab have doubled over three months after a series of cancer drug trial successes, CNBC Top News reported on November 3, 2026. The Danish biotech's gains have strengthened its push to own more of the medicines it develops. The report did not give the specific trial results or the company's financial figures.

Sources:CNBC Top News

1 outlet · 1 article · first seen Nov 3, 7:00 AM ET

What this touches in markets

Stored closes for the instruments tied to this story's tags and places, with their dates.

  • XLV closed at 184.60, down 0.15%, on 2026-11-02. Listed for: Health Care sector ETF.

Every source article